决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Primary Cutaneous Gamma-Delta T-Cell Lymphoma Complicating Long-Standing Immunosuppressed Dermatomyositis.
Primary Cutaneous Gamma-Delta T-Cell Lymphoma Complicating Long-Standing Immunosuppressed Dermatomyositis.
原发性皮肤γδT细胞淋巴瘤(PCGD-TCL)是一种罕见的细胞毒性淋巴瘤,其关键致癌驱动因素位于JAK/STAT通路。
原发性皮肤γδT细胞淋巴瘤(PCGD-TCL)是一种罕见的细胞毒性淋巴瘤,其关键致癌驱动因素位于JAK/STAT通路。皮下脂膜炎样T细胞淋巴瘤(SPTCL)同样主要累及皮下脂肪组织,在自身免疫性疾病背景下更为常见。SPTCL与狼疮性脂膜炎在临床病理上存在重叠。然而,自身免疫与PCGD-TCL之间的联系远不如前者明确,尤其是在长期免疫抑制性皮肌炎(DM)的情况下。我们报告两例PCGD-TCL,发生于患有慢性抗TIF1-γ DM的女性患者,均在多年免疫抑制治疗后发病。病例1为47岁女性,有19年DM病史,正在接受硫唑嘌呤/泼尼松治疗,出现快速进展的疼痛性皮下结节。切开活检证实为TCR-delta+、CD8+细胞毒性T细胞淋巴增殖性疾病(TCLPD),符合PCGD-TCL。经普拉曲沙及后续异基因造血干细胞移植后达到完全缓解。病例2为27岁女性,DM患者,正在接受霉酚酸酯/利妥昔单抗治疗,出现皮下结节,病程惰性,部分自行消退。活检显示类似的脂膜炎性浸润,伴非典型TCR-delta+、CD8+表型。值得注意的是,两例均未检出高危JAK/STAT通路突变。这些病例表明PCGD-TCLPD/TCL是慢性免疫抑制性DM的潜在并发症。共有的非典型CD8+免疫表型及缺乏经典驱动突变提示一种可能与长期免疫调节相关的独特致病机制。与以侵袭性病程和<2年中位生存期为特征的经典PCGD-TCL不同,这两例的临床病程各异,一例需要移植,另一例则表现为惰性行为并对治疗有反应。
Primary cutaneous gamma-delta T-cell lymphoma (PCGD-TCL) is a rare cytotoxic lymphoma with key oncogenic drivers in the JAK/STAT pathway. Also primarily involving the subcutaneous adipose tissue, subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is more frequently encountered in scenarios of autoimmune disorders. SPTCL shares clinicopathologic overlap with lupus panniculitis. However, the link between autoimmunity and PCGD-TCL is much less established, particularly in the setting of long-standing, immunosuppressed dermatomyositis (DM). We report two cases of PCGD-TCL arising in women with chronic anti-TIF1-γ DM following years of immunosuppressive therapy. Case 1 is a 47-year-old woman with a 19-year history of DM on azathioprine/prednisone who developed rapidly progressive, painful subcutaneous nodules. Incisional biopsy confirmed a TCR-delta+, CD8+ cytotoxic T-cell lymphoproliferative disorder (TCLPD) compatible with PCGD-TCL. She achieved complete remission following pralatrexate and subsequent allogeneic hematopoietic stem cell transplant. Case 2 is a 27-year-old woman with DM on mycophenolate/rituximab who developed subcutaneous nodules with an indolent course and some spontaneous regression. A biopsy revealed a similar panniculitic infiltrate with an atypical TCR-delta+, CD8+ phenotype. Notably, both cases were negative for high-risk JAK/STAT pathway mutations. These cases identify PCGD-TCLPD/TCL as a potential complication of chronic, immunosuppressed DM. The shared, atypical CD8+ immunophenotype and absence of canonical driver mutations suggest a distinct pathogenic mechanism possibly linked to long-term immune modulation. Unlike classic PCGD-TCL, which is characterized by an aggressive course and < 2-year median survival, the clinical courses in these two cases were variable, with one requiring transplant and the other showing indolent behavior and responsiveness to therapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。